CA3083499A1 — Methods of treatment with asparaginase
Assigned to Jazz Pharmaceuticals Ireland Ltd · Expires 2019-06-06 · 7y expired
What this patent protects
Provided herein are protein conjugates that include L-asparaginase from Erwinia and polyethylene glycol. The present invention also discloses uses of the protein conjugates for treating diseases treatable by L-asparagine depletion in patients such as cancer. Further disclosed her…
USPTO Abstract
Provided herein are protein conjugates that include L-asparaginase from Erwinia and polyethylene glycol. The present invention also discloses uses of the protein conjugates for treating diseases treatable by L-asparagine depletion in patients such as cancer. Further disclosed herein are uses of the protein conjugates for manufacturing medicaments for treating diseases treatable by L-asparagine depletion in patients.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.